HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.

AbstractBACKGROUND:
Immunoglobulin (Ig)-related amyloidosis is the most common type of systemic amyloidosis in the developed countries and involves the kidney in most cases. Clinical remission can be achieved with chemotherapy and/or autologous stem cell transplantation (ASCT). Previous case reports have showed persistence of renal amyloid mass in light-chain amyloidosis (AL) even in the setting of hematologic and renal response.
METHODS:
We report a novel finding in two cases of heavy- and light-chain amyloidosis (AHL) in which monoclonal Ig but not serum amyloid P (SAP), apolipoprotein E (ApoE) or amyloid bulk in the kidney regressed after successful therapy.
RESULTS:
In the pre-treatment renal biopsies, the amyloid deposits stained for one heavy and one light chains (IgG + λ in one case and IgA + κ in one case). Laser microdissection followed by mass spectrometry (LMD/MS) in both cases showed abundant spectra for Ig heavy and light chains, SAP and ApoE. Both patients achieved a hematologic response with disappearance of the monoclonal protein from serum and urine and normalization of serum-free light chain ratio, but renal response occurred in only one patient. Repeat kidney biopsies showed persistence of fibrillar amyloid deposits, but regression of Ig from the amyloid deposits based on immunofluorescence. LMD/MS on the repeat biopsy performed in one case also showed disappearance of Ig but not SAP or ApoE.
CONCLUSIONS:
Our finding suggests that effective chemotherapy and/or ASCT in some patients with AHL not only eliminates the circulating pathogenic monoclonal Ig but also the Ig component of amyloid deposits, which may translate into renal response. This, however, may not lead to regression of amyloid deposits themselves. The latter may require more time or addition of therapeutic agents that target amyloid-associated proteins such as SAP, which are not commercially available.
AuthorsSami Safadi, Ahmed Saad, Patrick S Quint, Sanjeev Sethi, Nelson Leung, Paul Kurtin, Samih H Nasr
JournalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (Nephrol Dial Transplant) Vol. 30 Issue 7 Pg. 1151-5 (Jul 2015) ISSN: 1460-2385 [Electronic] England
PMID25796445 (Publication Type: Case Reports, Journal Article)
Copyright© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Chemical References
  • Immunoglobulin Heavy Chains
  • Immunoglobulin Light Chains
Topics
  • Amyloidosis (metabolism, pathology, therapy)
  • Fluorescent Antibody Technique
  • Humans
  • Immunoglobulin Heavy Chains (metabolism)
  • Immunoglobulin Light Chains (metabolism)
  • Laser Capture Microdissection
  • Male
  • Mass Spectrometry
  • Middle Aged
  • Plaque, Amyloid (metabolism, pathology, therapy)
  • Stem Cell Transplantation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: